LCTX Stock — Lineage Cell Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.03

Market cap

$260.5M

Cash

$50.8M

Enterprise value

$209.7M

Balance sheet

Cash	$50.8M
Debt	$0.0M
Net cash	$50.8M
Enterprise value	$209.7M
Basic shares	252.9M shares
Fully diluted shares	355.1M shares
Fully diluted market cap	$365.8M
Cash per share	$0.20

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading LCTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 21 - Nov 2	OPC1	Phase 1	Spinal Cord Injury Cervical; Spinal Cord Injury Thoracic; Spinal Cord Injury, Acute	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

OpRegen

Phase 2 · Active Modality: allogeneic cell therapy

Partnerships Roche: worldwide collaboration and license agreement (exclusive worldwide rights to RPE cell therapies including OpRegen for ocular disorders); $50.0M upfront, $5.0M milestone received December 2025, tiered double-digit U.S. royalties

Indications

Geographic atrophy (GA) secondary to AMD (Phase 2)

Status note Lead program; allogeneic retinal pigmented epithelial (RPE) cell replacement therapy currently in Phase 2a development (GAlette study ongoing in Israel).

ReSonance

Preclinical · Active

Aliases ANP1

Partnerships William Demant Invest (WDI): research collaboration agreement (August 2025) to advance preclinical development for hearing loss

Indications

Hearing loss (auditory neuropathy) (Preclinical)

Status note Preclinical program for hearing loss; novel deafening model established to support functional preclinical testing under the WDI collaboration.

OPC1

Phase 1 · Active Modality: cell therapy

Status note Filing references a completed device study at UC San Diego Health in which the novel delivery system successfully administered a one-time injection of OPC1; no indication or trial phase beyond that is stated in the excerpts.

VAC2

Phase 1 · Active Modality: cell therapy

Partnerships Cancer Research UK (CRUK): clinical trial and option agreement; Lineage exercised early its option to acquire data from the CRUK-conducted Phase 1 trial

Indications

Non-small cell lung cancer (Phase 1)

Status note Phase 1 clinical trial in non-small cell lung cancer being conducted by CRUK.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	OPC1
Lead indication	Spinal Cord Injury Cervical
Lead phase	Phase 1
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06841770	Phase 1	Recruiting	Sponsor	LCTX	—	Spinal Cord Injury Cervical; Spinal Cord Injury Thoracic; Spinal Cord Injury, Acute	—
NCT05919563	Not disclosed	Active, not recruiting	Sponsor	LCTX	—	Spinal Cord Injuries	—
NCT05975424	Not disclosed	Active, not recruiting	Sponsor	LCTX	—	Spinal Cord Injuries	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Lineage Cell Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

LCTX — Lineage Cell Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials